Pacific Shuanglin Bio-Pharmacy000403.SZValuation Analysis

As of Oct 19, 2026, Pacific Shuanglin Bio-Pharmacy (000403.SZ) trades at a P/E of 33.70x, P/B of 1.13x, P/S of 5.44x, and a dividend yield of 0.00%.
Longitudinal percentile comparison: P/E sits at the 38th percentile over the trailing 10Y window (vs. 83rd percentile over 3Y); P/B sits at the 1st percentile over the trailing 10Y window (vs. 2nd percentile over 3Y); P/S sits at the 5th percentile over the trailing 10Y window (vs. 17th percentile over 3Y).
Cross-sectional valuation: its P/E ranks at the 46th percentile within its industry and the 46th percentile across the broader market.
Shareholder return highlight: Total Shareholder Yield is 0.00%; its historical percentile over the trailing long-term window is still accumulating data.
The P/E and P/B percentiles diverge here, differing by 37.9 points — relying on either metric alone could be misleading. Its P/E percentile is roughly the same whether measured against the industry or the broader market. Shareholder returns here are driven almost entirely by cash dividends, with minimal contribution from buybacks. Pacific Shuanglin Bio-Pharmacy operates in the Medicine sector. Data refreshes weekly and is for reference only, not investment advice.